Latest News

Sinclair NASDAQ: SBGI reported higher second-quarter revenue and adjusted EBITDA as early political advertising demand, distribution revenue growth and expense discipline offset softer core advertisin

Schrodinger NASDAQ: SDGR said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers

Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operat

Cardlytics, Inc. (CDLX) Q2 2026 Earnings Call Transcript

Joby Aviation, Inc. (JOBY) Q2 2026 Earnings Call Transcript

Block, Inc. (XYZ) Q2 2026 Earnings Call Transcript

Jamie Dimon said AI spending in the US is likely to pay off. He said data center construction has boosted the US GDP, creating jobs and demand for construction materials.

Blue Bird Corporation (BLBD) Q3 2026 Earnings Call Transcript

The Chemours Company (CC) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

BrainsWay is transitioning from a device manufacturer to a capital-light ecosystem provider for interventional psychiatry, leveraging recurring revenue and minority investments. BWAY reported Q1-2026

AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript

Dave Inc. (DAVE) Q2 2026 Earnings Call Transcript

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript

Tutor Perini Corporation (TPC) Q2 2026 Earnings Call Transcript

ServiceNow remains a Strong Buy, with compelling growth, robust financials, and misunderstood AI integration driving upside potential. I'm closely monitoring Now Assist's path to $1B ACV, backlog and

OraSure Technologies NASDAQ: OSUR reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth i

Pacific Biosciences of California NASDAQ: PACB reported second-quarter 2026 revenue of $39 million, roughly flat from $39.8 million a year earlier, while announcing an immediate leadership transition